305 related articles for article (PubMed ID: 38601081)
1. Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions.
Zheng M; Kumar A; Sharma V; Behl T; Sehgal A; Wal P; Shinde NV; Kawaduji BS; Kapoor A; Anwer MK; Gulati M; Shen B; Singla RK; Bungau SG
Front Cell Dev Biol; 2024; 12():1353860. PubMed ID: 38601081
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
Tan F; Wahdan-Alaswad R; Yan S; Thiele CJ; Li Z
Cancer Sci; 2013 Dec; 104(12):1586-92. PubMed ID: 24011394
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeting therapies for neuroblastoma: Progress and challenges.
Zafar A; Wang W; Liu G; Wang X; Xian W; McKeon F; Foster J; Zhou J; Zhang R
Med Res Rev; 2021 Mar; 41(2):961-1021. PubMed ID: 33155698
[TBL] [Abstract][Full Text] [Related]
4. State of the art in immunotherapy of neuroblastoma.
Jabbari P; Hanaei S; Rezaei N
Immunotherapy; 2019 Jun; 11(9):831-850. PubMed ID: 31094257
[TBL] [Abstract][Full Text] [Related]
5. Narrative review: precision medicine applications in neuroblastoma-current status and future prospects.
Zhou J; Du H; Cai W
Transl Pediatr; 2024 Jan; 13(1):164-177. PubMed ID: 38323175
[TBL] [Abstract][Full Text] [Related]
6. ISL1 promoted tumorigenesis and EMT via Aurora kinase A-induced activation of PI3K/AKT signaling pathway in neuroblastoma.
Li M; Sun C; Bu X; Que Y; Zhang L; Zhang Y; Zhang L; Lu S; Huang J; Zhu J; Wang J; Sun F; Zhang Y
Cell Death Dis; 2021 Jun; 12(6):620. PubMed ID: 34131100
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions.
Joshi S
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722460
[TBL] [Abstract][Full Text] [Related]
8. From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.
Capasso M; Brignole C; Lasorsa VA; Bensa V; Cantalupo S; Sebastiani E; Quattrone A; Ciampi E; Avitabile M; Sementa AR; Mazzocco K; Cafferata B; Gaggero G; Vellone VG; Cilli M; Calarco E; Giusto E; Perri P; Aveic S; Fruci D; Tondo A; Luksch R; Mura R; Rabusin M; De Leonardis F; Cellini M; Coccia P; Iolascon A; Corrias MV; Conte M; Garaventa A; Amoroso L; Ponzoni M; Pastorino F
J Transl Med; 2024 Feb; 22(1):151. PubMed ID: 38351008
[TBL] [Abstract][Full Text] [Related]
9. Emerging therapeutic targets for neuroblastoma.
Aravindan N; Herman T; Aravindan S
Expert Opin Ther Targets; 2020 Sep; 24(9):899-914. PubMed ID: 33021426
[TBL] [Abstract][Full Text] [Related]
10. Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches.
Bottino C; Dondero A; Bellora F; Moretta L; Locatelli F; Pistoia V; Moretta A; Castriconi R
Front Immunol; 2014; 5():56. PubMed ID: 24575100
[TBL] [Abstract][Full Text] [Related]
11. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
12. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
[TBL] [Abstract][Full Text] [Related]
13. In Vitro Sensitivity Profiling of Neuroblastoma Cells Against A Comprehensive Small Molecule Kinase Inhibitor Library to Identify Agents for Future Therapeutic Studies.
Singh A; Meier-Stephenson V; Jayanthan A; Narendran A
Curr Cancer Drug Targets; 2017; 17(6):569-584. PubMed ID: 27875952
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathogenesis of peripheral neuroblastic tumors.
Janoueix-Lerosey I; Schleiermacher G; Delattre O
Oncogene; 2010 Mar; 29(11):1566-79. PubMed ID: 20101209
[TBL] [Abstract][Full Text] [Related]
15. RLIP76 Inhibition: A Promising Developmental Therapy for Neuroblastoma.
Singhal SS; Nagaprashantha L; Singhal P; Singhal S; Singhal J; Awasthi S; Horne D
Pharm Res; 2017 Aug; 34(8):1673-1682. PubMed ID: 28386633
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the Role of p53 and TAp73 in Neuroblastoma: From Pathogenesis to Treatment.
Almeida J; Mota I; Skoda J; Sousa E; Cidade H; Saraiva L
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551697
[TBL] [Abstract][Full Text] [Related]
17. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
Peirce SK; Findley HW
Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
[TBL] [Abstract][Full Text] [Related]
18. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
19. EGFR signaling defines Mclâ»1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
20. Cell death-based treatment of neuroblastoma.
Valter K; Zhivotovsky B; Gogvadze V
Cell Death Dis; 2018 Jan; 9(2):113. PubMed ID: 29371588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
